Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
phosphodiesterase/accident vasculaire cérébral
Le lien est enregistré dans le presse-papiers
13 résultats
Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The field relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The field further relates to inhibitors of
Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND
1. Field of the Invention
The present invention relates to a metabolite of a xanthine Phosphodiesterase type 5 ("PDE 5") inhibitor useful for treatment of erectile dysfunction, and derivatives, formulations and processes related thereto.
2. Background
U.S. patent application Ser. No.
Association of PDE4D allelic variants with stroke
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Recently the phosphodiesterase 4D (PDE4D) gene has been identified as a risk factor for ischemic stroke (Gretarsdottir, et al., Am J Hum Genet (2002) 70:593-603). Gretarsdottir et al. (2002) conducted a whole genome scan and found a linkage peak (LOD=4.4) on chromosome
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This application is related to, not a continuing case to U.S. Pat. Nos. 6,172,060, 6,197,778, 6,177,428, 6,172,068, 6,221,881, 6,232,321, 6,197,782, 6,133,272, and 6,211,179.
FIELD OF THE INVENTION
The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions comprising at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, at least one compound that donates, transfers or
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions comprising at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, at least one compound that donates, transfers or
Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Congestive heart failure affects an estimated 4.8 million Americans with over 400,000 new cases diagnosed each year. Despite incremental advances in drug therapy, the prognosis for patients with advanced heart failure remains poor with annual mortality exceeding 40 percent. Although heart
Uses
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The field relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The field further relates to inhibitors of
4-(or 5-) substituted catechol derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to 4-substituted or 5-substituted catechol derivatives that are useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of
Organic compounds
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue or in vascular smooth muscle). The invention
Organic compounds
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue or in vascular smooth muscle). The invention
Organic compounds
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue or in vascular smooth muscle). The invention
Combinations
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
COMBINATIONS
The present invention relates to a combination, especially a pharmaceutical composition, comprising (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one active ingredient selected from the group consisting of (i) an anti-diabetic agent; (ii) HMG-Co-A
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
